Pharmaceutical companies to participate in the exchange of sterilization and filtration technology
Release time:
2020-08-14
Pharmaceutical Company Participated in Sterilization and Filtration Technology Exchange
News # July 16 - 18 , Copart's 9th Sterilization and Filtration Technology and Verification Sharing Meeting was held in Hangzhou. Jianfeng Pharmaceutical Company sent personnel to participate in this sharing meeting to learn about sterilization and filtration technology and related knowledge of process verification.
Hangzhou Cobaite Filter Equipment Co., Ltd. is a global filter equipment enterprise, mainly engaged in the development of microporous membranes such as PES , PVDF , N66 , PTFE , and the design and manufacture of various folded membrane filter elements and filters. Since its establishment in 2003 , Coppert has held nine sessions of sterilization and filtration technology and verification sharing sessions, with more than ,600 pharmaceutical companies from mainland China, Hong Kong, Taiwan, Malaysia, Japan and other countries and regions participating, with extensive influence in the industry. Most of the three types of filter elements used by Jinxi Pharmaceutical Factory, namely, sterilization filtration, disinfectant filtration and air filtration, come from Cobaite Company. For this reason, the pharmaceutical company also sent special personnel to participate in this technical exchange.
In this training, the relevant staff of Copart Company and the experts from Zhejiang Certification Center and Guangdong Food and Drug Administration will discuss the quality management system of filter elements and filters, the Guidelines for Sterilization and Filtration Technology and Application, the core components of filter element process verification, endotoxin removal technology, and the remedy, correction and prevention of incomplete data, sterilization filter bacteria challenge test case, chemical compatibility and dissolution analysis method of defects (risk) discussion and case analysis, filter integrity test method and other related content were shared and introduced. After the meeting, the participants also visited the peripheral sites of the stainless steel filter workshop, filter element workshop and verification center of the company, and learned about the key control items of sterilization and filtration.
Through this sharing meeting, the participants of the pharmaceutical company have a deeper understanding and mastery of the relevant knowledge of filter element integrity test, endotoxin removal technology, solution to difficult problems in filtration process, filter element process verification and filter element application, and have a new understanding of product quality control. After the sharing meeting, the participants also exchanged views with experts from Coppert to discuss relevant matters concerning the verification of filter elements currently in use by the company. (Wang Xiaosheng Pan Xujun)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page